Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ankylosing Spondylitis: full-pipeline trial registry
7 of 16 indexed Ankylosing Spondylitis trials are currently recruiting.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 7 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Ankylosing Spondylitis: 16 US clinical trials tracked, 7 recruiting.
Ankylosing Spondylitis is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), running 2 of these trials.
Enrollment posture brief
Registry condition ankylosing-spondylitis
OPEN 7 | RECR 44% | LATE 3 | EARLY 2 | RANK #1060 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Distress Syndrome (44% recruiting · 32 trials)
Ankylosing Spondylitis lists 7 open slots (44% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ankylosing Spondylitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ankylosing Spondylitis is recruiting below its size-band peers.
7 of 16 indexed trials (43.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Ankylosing Spondylitis trials is spread across many organizations.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) accounts for 2 of 16 trials (12.5%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Ankylosing Spondylitis enrolment sits around 508 participants.
Median target enrolment is 508 among the 16 trials that report a genuine target (sentinel values excluded). 1 of those (6.3%) plan for fewer than 100 participants.
-
Ankylosing Spondylitis research leans observational.
6 interventional and 10 observational studies make up this index (37.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Sanguine Biosciences
NCT05635266
Exactech Shoulder Post Market Clinical Follow-up Study
Exactech
NCT05603728
Rheumatology Patient Registry and Biorepository
Yale University
NCT04402086
IMPACT - AndHealth Autoimmune Research Registry
AndHealth
NCT05883371
Rheumatology Diet Study
University of Central Florida
NCT06339957
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
TScan Therapeutics
NCT06587828
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
M.D. Anderson Cancer Center
NCT04751396
Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT02281747
OTIS Cimzia Pregnancy Registry
University of California, San Diego
NCT01797224
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
UCB Biopharma SRL
NCT04436640
Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity
Brigham and Women's Hospital
NCT05715463
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
Novartis Pharmaceuticals
NCT03259074
Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
Novartis Pharmaceuticals
NCT03350815
Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT00056719
Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis
Pfizer
NCT01786668
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
UCB Biosciences
NCT02154425
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Ankylosing Spondylitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ankylosing Spondylitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ankylosing Spondylitis page
16 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Ankylosing Spondylitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) sponsors the most Ankylosing Spondylitis trials on record, review their full trial history before evaluating a specific study. See National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ankylosing Spondylitis condition card totals 16 registered trials; most-linked intervention AIN457 150 mg; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.